Observational analysis shows links between clonal hematopoiesis, hematologic toxicity, and secondary malignancies after CAR-T therapy.
Figure S5. (A) Scatter plot of time to MDS/AML diagnosis after CAR-T versus prior lines of therapy, with best fitting line shown by linear regression.
No takes yet. Share an insight, caveat, or question.
Avigan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: